Search Results - "tyrosine kinase"

Evobrutinib, a covalent Bruton's tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants by Holger Scheible, Martin Dyroff, Annick Seithel‐Keuth, Eleanor Harrison‐Moench, Nadra Mammasse, Andreas Port, Angelika Bachmann, Jennifer Dong, Jan Jaap vanLier, William Tracewell, David Mitchell

Connect to this object online.

Testosterone secretion is affected by receptor tyrosine kinase c-Kit and anoctamin 1 activation in mouse Leydig cells by Eun-A Ko, Min Seok Woo, Dawon Kang

Connect to this object online.

Immunomodulatory Activity of the Tyrosine Kinase Inhibitor Dasatinib to Elicit NK Cytotoxicity against Cancer, HIV Infection and Aging by Andrea Rodríguez-Agustín, Víctor Casanova, Judith Grau-Expósito, Sonsoles Sánchez-Palomino, José Alcamí, Núria Climent

Connect to this object online.

Tyrosine kinase inhibitors targeting vascular endothelial growth factor and the risk of aortic dissection-A pharmacovigilance analysis by Michael Dörks, Kathrin Jobski, Stefan Herget‐Rosenthal, Falk Hoffmann, Antonios Douros

Connect to this object online.

PENAPISAN VIRTUAL BERBASIS STRUKTUR DARI DATABASE BAHAN ALAM ZINC SEBAGAI INHIBITOR BRUTON TYROSINE KINASE by Fauzan Zein Muttaqin, Wayan Ayu Puje Astuti, La Ode Aman, Ellin Febrina, Aiyi Asnawi

Connect to this object online.

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer by Zihong Wu, Jiamei Wang, Fengming You, Xueke Li, Chong Xiao

Connect to this object online.

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance by Tim Fischer, Abdulkarim Najjar, Frank Totzke, Christoph Schächtele, Wolfgang Sippl, Christoph Ritter, Andreas Hilgeroth

Connect to this object online.

COMPARING THE INCIDENCE AND RISK FACTORS ASSOCIATED WITH CORONARY ARTERY DISEASE IN PATIENTS RECEIVING BRUTON'S TYROSINE KINASE INHIBITORS by Niharika Baviriseaty, MD

Connect to this object online.

Nanoparticle-based targeted therapy through EGFR tyrosine kinase inhibitors and their recent advances in lung cancer therapy by Priyanka S. Waghmare, Anuruddha R. Chabukswar, Kunal G. Raut, Bhagyashree Gaikwad-Pawar, Swati C. Jagdale

Connect to this object online.

Cardiovascular toxicity risk assessment of tyrosine kinase inhibitors: a pharmacovigilance study using the VigiBase database by Yusuke Igawa, Yusuke Igawa, Hirofumi Hamano, Hirofumi Hamano, Satoru Esumi, Tatsuaki Takeda, Makoto Kajizono, Ryo Kikuoka, Ikuya Kimura, Yoshito Zamami, Yoshito Zamami

Connect to this object online.

Phenotype versus genotype to optimize cancer dosing in the clinical setting-focus on 5‐fluorouracil and tyrosine kinase inhibitors by Jennifer H. Martin, Peter Galettis, Alex Flynn, Jennifer Schneider

Connect to this object online.

In vitro PK/PD modeling of tyrosine kinase inhibitors in non‐small cell lung cancer cell lines by Linda Wanika, Neil D. Evans, Martin Johnson, Helen Tomkinson, Michael J. Chappell

Connect to this object online.

Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC by Weijie Ma, Jie Zeng, Shuai Chen, Yue Lyu, Kyra A. Toomey, Chinh T. Phan, Ken Y. Yoneda, Tianhong Li

Connect to this object online.

Delving into the Role of Receptor-like Tyrosine Kinase (RYK) in Cancer: In Silico Insights into Its Diagnostic and Prognostic Utility by Jessica Alejandra Zapata-García, Luis Felipe Jave-Suárez, Adriana Aguilar-Lemarroy

Connect to this object online.

BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia by Gustavo P. Amarante-Mendes, Aamir Rana, Tarcila Santos Datoguia, Nelson Hamerschlak, Gabriela Brumatti

Connect to this object online.

What Is the Role of HSCT in Philadelphia-Chromosome-Positive and Philadelphia-Chromosome-Like ALL in the Tyrosine Kinase Inhibitor Era? by Kim Vettenranta, Veronika Dobsinska, Gabriella Kertész, Peter Svec, Jochen Buechner, Kirk R. Schultz

Connect to this object online.

HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton's Tyrosine Kinase Inhibitor Ibrutinib by Ziwen Lu, Zhixin Wang, Zhigang Tu, Hanqing Liu

Connect to this object online.

Case report: ALK D1225N missense mutation in lung adenocarcinoma responds to tyrosine kinase inhibitors by Jianxin Chen, Junhui Wang

Connect to this object online.

Soluble fms-like tyrosine kinase 1 and placental growth factor ratio for predicting preeclampsia in elderly gravida by Vorapong Phupong, Wilasinee Areeruk, Patau Tantbirojn, Ruangsak Lertkhachonsuk

Connect to this object online.

Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer by Zhang H

Connect to this object online.